[Home]
[Full version]
Modified herpes virus keeps arteries 'free-flowing' following procedures
Jul 10 ,Medicine & Health
A genetically engineered herpes simplex virus, primarily known for causing cold sores, may help keep arteries “free-flowing” in the weeks following angioplasty or stent placement for patients, according to research published early in the online edition of PNAS (Proceedings of the National Academy of Sciences of the United States of America).
Christopher Skelly, MD, assistant professor of vascular surgery at the University of Chicago Medical Center, and the study’s lead author says, “One of the drawbacks of balloon angioplasty to open blocked arteries and the use of stents to keep them open is that arteries sometimes experience aggravation from the procedure. The balloon angioplasty, in addition to opening the artery can lead to smooth muscle cell proliferation, similar to formation of scar tissue, known as neointimal hyperplasia. This scar tissue can restrict blood flow not long after the procedures, leading to a recurrence of symptoms. A significant number of these cases end up requiring further intervention to address this complication.”
Researchers at the University of Chicago noted that in recent years, genetically engineered herpes simplex virus studied for its efficacy against malignant tumors of the central nervous system and the liver was blocking certain types of cell death and proliferation of surviving cells. They wanted to test this effect in arteries following angioplasty therapy.
The researchers studied a rabbit model that replicates the restenosis or renarrowing after angioplasty. Rabbits that underwent angioplasty alone experienced significant narrowing of the artery. Rabbits exposed to the herpes simplex virus during angioplasty had minimal changes in the arteries. The smooth muscle cell proliferation which causes the restenosis was very low in the group treated with herpes and remained high in the untreated group.
One undesirable, yet expected outcome of angioplasty and stent placement is the disruption of the artery’s endothelial layer, which forms the inner lining of the artery. Loss of this inner layer predisposes the artery to blood clot formation which has been a recent concern with drug eluting stents. The researchers found that the endothelial layer was partially restored at 14 days and completely restored at 28 days post-balloon angioplasty in the group treated with the herpes virus.
“The ability to target the smooth muscle cells that cause the narrowing, and regenerate the endothelial cell lining is an important finding,” noted Skelly.
“This study is an important step in the application of genetically engineered herpes simplex viruses for treatment of vascular disease," Skelly added. "It suggests that genetically engineered viruses may have a significant impact on the outcomes of angioplasty performed in humans. Human trials would be the next step to test this theory.”
Source: University of Chicago
Related stories:
New system devised to guide doctors treating patients with symptomatic myocardial bridging
What type of intervention, if any, should cardiologists offer their patients who have a heart abnormality called myocardial bridging and symptoms of heart problems?
Drug-releasing stents linked with decrease in procedures to unblock coronary arteries
The widespread adoption of the use of drug-releasing coronary artery stents into routine practice is associated with a decrease in the need for repeat procedures to unblock coronary arteries and also do not appear to increase the risk of death, compared to bare-metal stents, according to a study in the June 25 issue of
JAMA.
Drug-releasing stent shows promise for improving outcomes in patients with coronary artery disease
For patients who underwent angioplasty to open narrowed coronary arteries, the use of stents releasing the drug everolimus reduced the rate of renarrowing of the arteries and significantly reduced the risk of major cardiac events, compared to the widely-used paclitaxel-releasing stents, according to a study in the April 23/30 issue of JAMA.
Gap between sexes in care of common heart condition
Women with a common heart condition may receive a lower level of medical care compared to men with the same condition, according to researchers at the University of Aberdeen.
FSU researcher's 'mutant' proteins could lead to new treatment for heart disease
Heart damage due to blocked arteries remains the leading cause of disease and death in the Western world, but a Florida State University College of Medicine researcher is helping to open new pathways toward treating the problem.
New technique for treating blocked coronary arteries shows promise
George W. Vetrovec, M.D., chair of cardiology at the Virginia Commonwealth University Medical Center, known nationally for his study and treatment of coronary artery disease, says a new technique for treating blocked coronary arteries shows promise, but is best performed by experienced physicians.
Researcher transplants stem cells to try to save patients' legs
A Northwestern University Feinberg School of Medicine researcher has launched the first U.S. trial in which a purified form of subjects' own adult stem cells was transplanted into their leg muscles with severely blocked arteries to try to grow new small blood vessels and restore circulation in their legs.
Making emergency artery repair safer
Catheters outfitted with balloons, lasers, and miniature drills have made the treatment of blocked arteries virtually routine. These devices are used to clear plaque from many vessels including coronary, femoral, renal, and carotid arteries. Until recently, a misstep in the delicate procedure usually required risky emergency surgery. Now physicians are using the same technology used to open clogged arteries to repair ruptures and perforations with less risk.
[Home]
[Full version]